Maybe the faster we can get ArTiMist out there the better. It really has a compelling case and need if results are what we think they're going to be. With no refrigeration and little medical experience (if any) required, they can distribute it all over the place ready for use as required.
Following is further news released this week relating to trouser"s post. Interesting that Glaxo has already spent $300m on this vaccine. Imagine how many little bottles of ArTiMist we can distribute for those $'s.
"AN experimental malaria vaccine once thought promising is turning out to be a disappointment, with a new study showing it is only about 30 per cent effective at protecting infants from the killer disease. That is a significant drop from a study last year done in slightly older children, which suggested the vaccine cut the malaria risk by about half - though that is still far below the protection provided from most vaccines. According to details released on Friday, the three-shot regimen reduced malaria cases by about 30 per cent in infants aged six to 12 weeks, the target age for immunisation. Dr Jennifer Cohn, a medical co-ordinator at Doctors Without Borders, described the vaccine's protection levels as "unacceptably low". She was not linked to the study. Scientists have been working for decades to develop a malaria vaccine, a complicated endeavour since the disease is caused by five different species of parasites. There has never been an effective vaccine against a parasite. Worldwide, there are several dozen malaria vaccine candidates being researched. In 2006, a group of experts led by the World Health Organisation said a malaria vaccine should cut the risk of severe disease and death by at least half and should last longer than one year. Malaria is spread by mosquitoes and kills more than 650,000 people every year, mostly young children and pregnant women in Africa. Without a vaccine, officials have focused on distributing insecticide-treated bed nets, spraying homes with pesticides and ensuring access to good medicines. In the new study, scientists found babies who got three doses of the vaccine had about 30 per cent fewer cases of malaria than those who didn't get immunised. The research included more than 6,500 infants in Africa. Experts also found the vaccine reduced the amount of severe malaria by about 26 per cent, up to 14 months after the babies were immunised. Scientists said they needed to analyse the data further to understand why the vaccine may be working differently in different regions. For example, babies born in areas with high levels of malaria might inherit some antibodies from their mothers which could interfere with any vaccination. "Maybe we should be thinking of a first-generation vaccine that is targeted only for certain children," said Dr Salim Abdulla of the Ifakara Health Institute in Tanzania, one of the study investigators. Results were presented at a conference in South Africa on Friday and released online by the New England Journal of Medicine. The study is scheduled to continue until 2014 and is being paid for by GlaxoSmithKline and the PATH Malaria Vaccine Initiative. Glaxo first developed the vaccine in 1987 and has invested $US300 million ($A289.5 million) in it so far. WHO said it couldn't comment on the incomplete results and would wait until the trial was finished before drawing any conclusions."
